Your browser doesn't support javascript.
loading
Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice.
Raevens, Sarah; Geerts, Anja; Paridaens, Annelies; Lefere, Sander; Verhelst, Xavier; Hoorens, Anne; Van Dorpe, Jo; Maes, Tania; Bracke, Ken R; Casteleyn, Christophe; Jonckx, Bart; Horvatits, Thomas; Fuhrmann, Valentin; Van Vlierberghe, Hans; Van Steenkiste, Christophe; Devisscher, Lindsey; Colle, Isabelle.
Afiliação
  • Raevens S; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
  • Geerts A; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
  • Paridaens A; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
  • Lefere S; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
  • Verhelst X; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
  • Hoorens A; Department of Pathology, Ghent University and Ghent University Hospital, Ghent, Belgium.
  • Van Dorpe J; Department of Pathology, Ghent University and Ghent University Hospital, Ghent, Belgium.
  • Maes T; Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Bracke KR; Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Casteleyn C; Department of Morphology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
  • Jonckx B; Applied Veterinary Morphology, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium.
  • Horvatits T; ThromboGenics NV, Heverlee, Belgium.
  • Fuhrmann V; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Van Vlierberghe H; Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Van Steenkiste C; Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Devisscher L; Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Colle I; Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent University Hospital, Ghent, Belgium.
Hepatology ; 68(2): 634-651, 2018 08.
Article em En | MEDLINE | ID: mdl-29023811
Hepatopulmonary syndrome (HPS) is a severe complication of cirrhosis with increased risk of mortality. Pulmonary microvascular alterations are key features of HPS; but underlying mechanisms are incompletely understood, and studies on HPS are limited to rats. Placental growth factor (PlGF), a proangiogenic molecule that is selectively involved in pathological angiogenesis, may play an important role in HPS development; however, its role has never been investigated. In this study, we validated an HPS model by common bile duct ligation (CBDL) in mice, investigated the kinetic changes in pulmonary angiogenesis and inflammation during HPS development, and provide evidence for a novel therapeutic strategy by targeting pathological angiogenesis. Mice with CBDL developed hypoxemia and intrapulmonary shunting on a background of liver fibrosis. Pulmonary alterations included increased levels of proangiogenic and inflammatory markers, which was confirmed in serum of human HPS patients. Increased PlGF production in HPS mice originated from alveolar type II cells and lung macrophages, as demonstrated by immunofluorescent staining. Dysfunctional vessel formation in CBDL mice was visualized by microscopy on vascular corrosion casts. Both prophylactic and therapeutic anti-PlGF (αPlGF) antibody treatment impeded HPS development, as demonstrated by significantly less intrapulmonary shunting and improved gas exchange. αPlGF treatment decreased endothelial cell dysfunction in vivo and in vitro and was accompanied by reduced pulmonary inflammation. Importantly, αPlGF therapy did not affect liver alterations, supporting αPlGF's ability to directly target the pulmonary compartment. CONCLUSION: CBDL in mice induces HPS, which is mediated by PlGF production; αPlGF treatment improves experimental HPS by counteracting pulmonary angiogenesis and might be an attractive therapeutic strategy for human HPS. (Hepatology 2017).
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Hepatopulmonar / Fator de Crescimento Placentário / Pulmão / Neovascularização Patológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Hepatology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Hepatopulmonar / Fator de Crescimento Placentário / Pulmão / Neovascularização Patológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Hepatology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica